Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397


Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.

Kim E, Zschiedrich S.

Front Pediatr. 2018 Feb 9;6:16. doi: 10.3389/fped.2018.00016. eCollection 2018. Review.


PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.

Zhao B, Liu L, Mao J, Zhang Z, Wang Q, Li Q.

Cell Death Dis. 2018 Feb 22;9(3):307. doi: 10.1038/s41419-018-0348-9.


Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.

Martin-Sanchez D, Fontecha-Barriuso M, Sanchez-Niño MD, Ramos AM, Cabello R, Gonzalez-Enguita C, Linkermann A, Sanz AB, Ortiz A.

Cell Death Dis. 2018 Jan 25;9(2):118. doi: 10.1038/s41419-017-0043-2. Review.


Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation.

Hasumi H, Yao M.

Cancer Sci. 2018 Mar;109(3):581-586. doi: 10.1111/cas.13503. Epub 2018 Feb 15. Review.


Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.

Garrigós C, Espinosa M, Salinas A, Osman I, Medina R, Taron M, Molina-Pinelo S, Duran I.

Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.


Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis.

Espana-Agusti J, Warren A, Chew SK, Adams DJ, Matakidou A.

Nat Commun. 2017 Dec 11;8(1):2026. doi: 10.1038/s41467-017-02245-1.


MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.

Schanza LM, Seles M, Stotz M, Fosselteder J, Hutterer GC, Pichler M, Stiegelbauer V.

Int J Mol Sci. 2017 Nov 22;18(11). pii: E2495. doi: 10.3390/ijms18112495. Review.


ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma.

Wang D, Song L, Wang L, Zhao L, Xiang B, Li Y, Shan B, Liu J.

Oncotarget. 2017 Sep 21;8(49):86325-86338. doi: 10.18632/oncotarget.21149. eCollection 2017 Oct 17.


Hypoxia-Inducible Factors and Cancer.

Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY.

Curr Sleep Med Rep. 2017 Mar;3(1):1-10. doi: 10.1007/s40675-017-0062-7. Epub 2017 Jan 28.


New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Crona J, Taïeb D, Pacak K.

Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062.


Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.

Mehdi A, Riazalhosseini Y.

Int J Mol Sci. 2017 Aug 16;18(8). pii: E1774. doi: 10.3390/ijms18081774. Review.


The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

Kaelin WG Jr.

Trans Am Clin Climatol Assoc. 2017;128:298-307.


Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients.

Wang JY, Peng SH, Ning XH, Li T, Liu SJ, Liu JY, Hong BA, Qi NN, Peng X, Zhou BW, Zhang JF, Cai L, Gong K.

Cancer Med. 2017 Sep;6(9):2131-2141. doi: 10.1002/cam4.1134. Epub 2017 Aug 4.


Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.

Sun W, Kato H, Kitajima S, Lee KL, Gradin K, Okamoto T, Poelllinger L.

Sci Rep. 2017 Aug 3;7(1):7190. doi: 10.1038/s41598-017-05685-3.


Genetic alterations in Japanese extrahepatic biliary tract cancer.

Noguchi R, Yamaguchi K, Ikenoue T, Terakado Y, Ohta Y, Yamashita N, Kainuma O, Yokoi S, Maru Y, Nagase H, Furukawa Y.

Oncol Lett. 2017 Jul;14(1):877-884. doi: 10.3892/ol.2017.6224. Epub 2017 May 22.


Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.

Wang Y, Yang J, Du G, Ma D, Zhou L.

Mol Carcinog. 2017 Oct;56(10):2342-2351. doi: 10.1002/mc.22688. Epub 2017 Jun 30.


Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium.

Hasegawa H, Kusumi Y, Asakawa T, Maeda M, Oinuma T, Furusaka T, Oshima T, Esumi M.

BMC Cancer. 2017 May 26;17(1):381. doi: 10.1186/s12885-017-3364-8.


Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.

Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK.

Ther Adv Med Oncol. 2017 Apr;9(4):287-298. doi: 10.1177/1758834016687261. Epub 2017 Feb 14. Review.


Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, Madhuranthakam AJ, Pedrosa I, Wang T, Dey A, Busslinger M, Xie XJ, Hammer RE, McKay RM, Kapur P, Brugarolas J.

Cancer Discov. 2017 Aug;7(8):900-917. doi: 10.1158/2159-8290.CD-17-0292. Epub 2017 May 4.


Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients.

Peng S, Shepard MJ, Wang J, Li T, Ning X, Cai L, Zhuang Z, Gong K.

Oncotarget. 2017 Jun 13;8(24):38456-38465. doi: 10.18632/oncotarget.16594.

Supplemental Content

Support Center